文献速递胸部肿瘤放疗放疗物理与技术

肺癌立体定向消融放疗后RECIST标准的预测价值如何

What is the predictive value of RECIST criteria following stereotactic lung radiation?
PubMed 文献 · Radiother Oncol · 2023-10-31

本研究回顾2010至2015年接受肺立体定向消融放疗(SABR)的原发性肺癌或寡转移患者,评估RECIST标准判定进展性疾病(PD)的频率及其与真实治疗结局的相关性。88个病灶中66%(58/88)符合RECIST的PD标准,但仅16%(9/58)确认局部复发,RECIST定义PD的阳性预测值(PPV)为0.16,提示RECIST在该场景下预测价值有限。

要点

  • 肺SABR后66%(58/88)病灶符合RECIST的PD标准,但仅16%(9/58)确认局部复发。
  • RECIST定义PD的阳性预测值为0.16;12个月内触发PD者PPV为0.08,12个月后触发者为0.21。
  • 多数(47/58,81%)RECIST判定PD的病灶最终并非复发,仅少数(2/58,3%)反应不确定。

核心结论

  • 使用RECIST标准,三分之二接受肺SABR的患者符合PD标准,但仅少数存在复发,导致RECIST的PPV较差,凸显其在该场景下的局限性,并为医生解读肺SABR后影像提供参考。

研究设计与样本

  • 回顾性分析2010至2015年因原发性肺肿瘤或寡转移接受肺SABR的患者,SABR剂量为54-60 Gy分3-8次。
  • 共88个病灶纳入分析,其中75个为原发性肺癌,13个为肺转移。
  • 中位随访52个月(四分位距:33-68)。
  • 对所有随访扫描进行评估,连续测量治疗病灶,采用轴位CT切片上的最大直径进行RECIST计算。
  • 最终「金标准」反应评估基于PD后的大小变化,以及可获得的PET扫描和/或活检。

主要发现

  • 三分之二(66%,58/88)的治疗病灶符合RECIST的PD标准,但仅16%(9/58)的病例确认局部复发。
  • 多数RECIST触发PD的病灶(47/58,81%)最终未表现为复发,少数(2/58,3%)反应不确定。
  • RECIST定义PD事件的阳性预测值(PPV)为0.16。
  • 若PD在治疗后12个月内触发,PPV为0.08;相比之下,12个月后触发PD的病灶PPV为0.21。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Response EvaluationCriteriain Solid Tumors (RECIST) is commonly used to assess response to anti-cancer therapies. However, its application after lung stereotactic ablative radiotherapy (SABR) is complicated by radiation-induced lung changes. This study assesses the frequency of progressive disease (PD) by RECIST following lung SABR and correlates this with actual treatment outcomes as determined by longitudinal follow-up. METHODS AND MATERIALS: We reviewed patients treated with lung SABR for primary lung tumors or oligometastases between 2010 and 2015. Patients were treated with SABR doses of 54-60 Gy in 3-8 fractions. All follow-up scans were assessed and the treated lesion was serially measured over time, with the maximum diameter on axial CT slices used for RECIST calculations. Lesions demonstrating PD by RECIST criteria were identified and subsequently followed for long-term outcomes. The final 'gold-standard' assessment of response was based on size changes after PD and, as available, positron emission tomography scan and/or biopsy. RESULTS: Eighty-eight lesions met inclusion criteria. Seventy-five were lung primaries and thirteen were lung metastases. Median follow-up was 52 months (interquartile range: 33-68). Two-thirds (66 %, 58/88) of treated lesions met RECIST criteria for PD; however, local recurrence was only confirmed in 16 % (9/58) of cases. Most lesions that triggered PD by RECIST (47/58, 81 %) were ultimately found not to represent recurrence, while a minority (2/58, 3 %) had an uncertain response. The positive predictive value [PPV] of a RECIST defined PD event was 0.16. If PD was triggered within 12-months post-treatment, PPV was 0.08, compared to 0.21 for lesions triggering PD after 12-months. CONCLUSION: Using RECIST criteria, two-thirds of patients treated with lung SABR met criteria for PD. However, only a minority had recurrence, leading to a poor PPV of RECIST. This highlights the limitations of RECIST in this setting and provides context for physicians when interpreting post-lung SABR imaging.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Gulstene S, Lang P, Melody Qu X, et al. What is the predictive value of RECIST criteria following stereotactic lung radiation? Radiother Oncol. 2023. PMID: 37918636. doi:10.1016/j.radonc.2023.109976

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。